1 INTRODUCTION {#SEC1}
==============

A key goal in human genetics is to identify the functional DNA variants that give rise to phenotypic differences among individuals. Recent studies of complex diseases and phenotypes have tended to focus on genome-wide association studies (GWAS) employing hundreds of thousands of single nucleotide polymorphisms (SNPs). GWAS target common DNA variants, which could either directly contribute to the clinical phenotype or provide an indirect proxy for functional variants, which are in linkage disequilibrium (LD) with the SNP being tested. Distinguishing between direct, mechanistic contributions emanating from the functional variants themselves and indirect associations resulting from LD is challenging and improved methods are needed. One feasible solution is to catalog all DNA variants in the LD region of the association, both common and rare, by utilizing next-generation sequencing (NGS) technology.

The large number of variants that will be identified generates an urgent need for bioinformatics and computational approaches capable of prioritizing the variants most likely to underlie the observed association, for further biological testing. Non-synonymous substitutions within coding regions directly affect protein structure and are likely to affect protein function; a variety of algorithms, including PolyPhen ([@B35]), SIFT ([@B30]), TopoSNP ([@B42]), PMUT ([@B13]), LS-SNP ([@B24]), SNPeffect v2.0 ([@B36]), SNPs3D ([@B46]) and PolyDoms ([@B22]), were designed to identify functional non-synonymous substitutions. Synonymous coding variants may also exert phenotypic effect by influencing the conformation, splicing and stability of pre-mRNAs or by altering the expression level of a given protein ([@B3]; [@B20]; [@B25]). Coding sequences make up \<2% of the human genome ([@B12]). The regulatory component of the human genome is much less well defined but based upon conservation is 2 to 3 times larger than the coding region ([@B6]). Regulatory variants can affect the transcription initiation rate ([@B29]), microRNA binding and protein expression ([@B32]), but are far more difficult to identify. It should therefore come as no surprise that many of the variants associated with common, complex disease by GWAS do not alter coding sequences but rather occur within the non-coding regions of genes or intergenic regions ([@B4]; [@B9]; [@B16]; [@B18]; [@B23]).

Tools such as FASTSNP ([@B45]), PupaSuite ([@B5]) and SNPlogic ([@B33]), have been designed to identify SNPs residing in known transcription factor binding sites (TFBSs), and exonic splice enhancers/silencers. [@B27]) developed a scoring system for SNP prioritization that combines results from multiple independent prediction tools, using a probabilistic framework. The predictions made by these methods are not phenotype-specific, since they are based only upon our knowledge of the binding characteristics of known trans-acting regulatory factors. [@B31]) recently proposed a novel method for the prioritization of causal SNPs that employs an empirical methodology that accounts for local LD structure and integrates expression quantitative trait loci (eQTLs) and GWAS results in order to reveal the subset of association signals that are due to *cis* eQTLs. However, this algorithm does not consider sequence features of protein--DNA binding sites, and requires gene expression data, which is not always available for a given tissue and, more importantly, in the right biological context.

To address these limitations, we present a bioinformatics approach, *regSNPs*, which prioritizes transcriptional regulatory SNPs in LD regions detected by GWAS or linkage studies by integrating existing bioinformatics tools. We tested our model by assessing its ability to identify mutations logged in the Human Gene Mutation Database (HGMD) ([@B41]), a comprehensive collection of gene mutations underlying or associated with human inherited disease. The accuracy of our approach varies among diseases, with the area under the curve (AUC) of the receiver operating characteristics (ROC) curve ranging from 53.7% in schizophrenia to 77.9% in breast cancer. We applied our method to a region on chromosome 1q that had previously been found through linkage and association analysis to harbor genetic factors that contribute to the variation of femoral neck and lumbar spine bone mineral density (BMD) in premenopausal white women ([@B21]). Three SNPs were selected as likely to be functional, with an estimated false discovery rate (FDR) \<25%. They were then further tested for influence on transcription *in vitro*. Our results suggest that the proposed approach should be well suited for prioritizing transcriptional regulatory SNPs within the chromosomal regions found to be associated with a disease or phenotype.

2 METHODS {#SEC2}
=========

2.1 Data source and materials {#SEC2.1}
-----------------------------

SNPs in HapMap release 27 derived from Utah residents with ancestry from Northern and Western Europe (CEU) were used. Promoter regions were defined as between upstream 3000 bp and downstream 1000 bp from transcriptional start sites of genes based on RefSeq annotation. A total of 96 069 promoter SNPs were identified; 10 000 were randomly selected as the background when generating the empirical *P*-values for the significance of effects on binding affinity of each transcription factor. While applying *regSNPs* to a BMD-related region, 51 promoter SNPs were analyzed.

The TRANSFAC 9.2 database ([@B44]), which contains information on experimentally validated human TFBSs, was used as the source of binding information for known transcription factors. We selected 323 of the 459 human transcription factors for further study, because the rest of them do not have detailed sequences for TFBSs. These yielded 301 TFBSs. A negative control set of 10 000 promoter sequences in the human genome was randomly selected to represent putatively non-binding sequences for each TFBS.

The OMIM database ([@B28]) and the HGMD 2009.1 database ([@B41]) provide disease-related genes and mutations, respectively; both contain experimental validated data. For the purposes of analysis, we selected 13 disease states with at least two related genes in OMIM and at least nine promoter mutations documented in HGMD for model evaluation.

2.2 Evaluating the effect of a SNP on the binding affinity of a transcription factor {#SEC2.2}
------------------------------------------------------------------------------------

For a given SNP *V*, we estimated its effect on the binding of a particular transcription factor *tf*, denoted by the matching score *S*~*tf*~(*V*), by evaluating the binding affinity differences between reference and alternative alleles; the binding affinity was calculated using the position weight matrices (PWMs) documented in the TRANSFAC database using previously published methods ([@B43]). where *w* is the width (base pair) of the binding site, *k* represents the index of the 2*w* potential binding sites that contain the candidate variants on both the positive and negative strands. *N*~*t*~ is the total number of experimentally validated binding sequences for each TFBS in the TRANSFAC database; *b*~*ij*~ is the number of counts of the *i*-th nucleotide at the *j*-th position in the PWM; and *d*~*i*~ represents the percentage of the *i*-th nucleotide (A, C, G or T) in the human genome.

For each TFBS, we calculated the distributions of matching scores for both binding (*f*~*b*,*tf*~) and non-binding (*f*~*n*,*tf*~) events, based on the matching scores with the experimentally determined binding sites (documented in the TRANSFAC database) and randomly selected genomic sequences. The potential for a specific variant to change binding affinity of a TF was estimated as: where *S*~*VR*~ and *S*~*VA*~ denotes the matching scores \[defined in Equation ([1](#M1){ref-type="disp-formula"})\] of the specific transcription factor (*tf*) binding sites on the reference and alternative alleles, respectively. Equation ([2](#M2){ref-type="disp-formula"}) therefore represents the logarithmic odds ratio that two alleles fell within different distributions (binding or non-binding). A positive and negative Δ*S*~*V*~ implies that the alternative allele will result in a gain or loss of binding affinity, respectively. For each TF binding site, a *P*-value *P*~*tf*~(*V*) was further calculated for each variant, by calculating the percentage of 10 000 randomly selected HapMap ([@B15]) promoter SNPs that have \|Δ*S*~*tf*~\| scores greater than the variant \|Δ*S*~*V*~\| being evaluated.

2.3 Final ranking estimation for each variant {#SEC2.3}
---------------------------------------------

We combined the rankings from the previous two steps of *regSNPs* to derive a final score, *PS*(*V*), for each SNP; this score weights the likelihood that the observed SNP affects the binding of a transcription factor as well as the likelihood that the transcription factors are important in the corresponding phenotype. where *i* represents all the transcription factors in the TRANSFAC database, *P*~*tf*~*i*~~(*V*) indicates the significance of effects on binding affinity of transcription factor *i*, while *P*~*E*~(*tf*~*i*~) denotes the ranking scores, as the output of *Endeavour*, a knowledge-learning tool for gene prioritization ([@B1]), to represent the significance of prioritized gene (transcription factor *i*). A lower *PS* score implies a stronger relationship between the candidate SNP and the disease/phenotype being studied.

2.4 ROC curve of each disease {#SEC2.4}
-----------------------------

One thousand iterations, using a different negative set of randomly sampled regulatory SNPs were generated for each of the 13 disease states (e.g. diabetes) under study. For each iteration, we first ranked all candidate variants (both experimentally validated and randomly selected) by their final *PS* scores \[Equation ([3](#M3){ref-type="disp-formula"})\]. Then, we used a range of different thresholds, ranking SNPs/mutations from the lowest to highest *PS* scores, to select the positive mutations (scores lower than the threshold) which are recognized by *regSNPs* as being causally related to disease as well as negative mutations (scores higher than the threshold). In this way, one threshold can generate one pair of specificity--sensitivity values which we then used to plot the ROC curve. The AUC of the ROC is an average derived from those 1000 iterations.

2.5 FDR calculation {#SEC2.5}
-------------------

A *P*-value was calculated for each of the 51 promoter SNPs based on their priority score *PS*(*V*) \[Equation ([3](#M3){ref-type="disp-formula"})\], using permutation analysis of 1000 iterations. In each iteration, priority scores *PS*~*r*~(*V*) of 51 randomly selected promoter SNPs were calculated. This composes a priority score distribution for non-functional SNPs. A *P*-value was calculated for each of the 51 SNPs by using the percentile of their priority scores in the null distribution. FDR was further calculated using Benjamini--Hochberg methods ([@B2]).

2.6 Luciferase reporter assay {#SEC2.6}
-----------------------------

The 2-kb region upstream of *SLC39A1* exon 1 was amplified from International HapMap Project DNA samples NA07345 (AA at rs6661009) and NA12248 (CC at rs6661009) (TT and GG in the orientation of the gene), using primers tagged with restriction sites (underlined) \[forward: 5′-GATC [GAATTC]{.ul}CTTGAGCCCAAGATGTTGAGG ([EcoRI]{.ul}) and reverse: 5′-GATC[GAGCTC]{.ul}GAACAGCCAAACTGTCTCCG ([SacI]{.ul})\]. The amplicons were then cloned into the EcoRI/SacI restriction sites of the pGLuc-Basic vector (New England Biolabs, Ipswich, MA, USA). The 2-kb region upstream of *TPM3* exon 1 was amplified from NA12874 (GG at rs11265251), using nested PCR. First, a 2.3-kb fragment harboring the 2-kb region was amplified, using primers \[forward: 5′-GATC [GAATTC]{.ul}TCGTGATCCACCTGCCTCAG ([EcoRI]{.ul}) and reverse: 5′-GATC[GAGCTC]{.ul}GTGCCCACCCAGCTACTGCT ([SacI]{.ul})\]. Then, this first reaction was used to amplify the 2-kb region, using nested primers \[forward: 5′-GATC [GAGCTC]{.ul}CAGGTGTGCACCACCACACCCG ([SacI]{.ul}) and reverse: 5′-GATC [GAGCTC]{.ul}GTCCCTCTGCCGCGCCCT ([SacI]{.ul})\]. The amplicons were then cloned into the SacI restriction site of the pGLuc-Basic vector. The A allele of rs11265251 was created by site-directed mutagenesis, using the PCR overlap extension method ([@B17]; [@B19]). All inserts were sequenced to confirm that the nucleotides at rs6661009 and rs11265251 were the only differences introduced between the two *SLC39A1* and *TPM3* constructs, respectively.

Human embryonic kidney cells (HEK-293, American Type Culture Collection, Manassas, VA) were cultured in DMEM/F12 (1:1) (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS (Sigma-Aldrich, St Louis, MO, USA), sodium pyruvate (1 mM), [l]{.smallcaps}-Glutamine (2 mM), Penicillin (100 U/ml) and Streptomycin (100 μg/ml). 4 × 10^5^cells were plated into each well of a 24-well plate and after 24 h, transfected with 800 ng pGLuc-Basic vector, *SCL39A1* or *TPM3* constructs. In addition, 80 ng pSV40-CLuc control plasmid (New England Biolabs) was co-transfected to allow normalization of transfection efficiency. Transfections were performed in triplicate, using Lipofectamine 2000 (Invitrogen). Media collected at 24-h post-transfection (20 μl) were assayed in triplicate for luciferase activity in Centro LB 960 Luminometer (Berthold Technologies, Oak Ridge, TN, USA), using the BioLux *Cypridina* Luciferase Assay Kit and the BioLux *Gaussia* Luciferase Assay kit (New England Biolabs). Data from three independent experiments were analyzed by paired Student\'s *t*-tests. *P*\<0.05 were considered statistically significant.

3 RESULTS {#SEC3}
=========

3.1 Principles of SNP prioritization by *regSNPs* {#SEC3.1}
-------------------------------------------------

We propose a novel, integrative approach that employs a combination of existing bioinformatics tools to prioritize known SNPs found in or around the promoters (defined as −3000 to +1000 bp from the transcriptional start site, see [Section 2](#SEC2){ref-type="sec"}) of high priority candidate genes related to a specific phenotype or disease. Our strategy contains three major steps ([Fig. 1](#F1){ref-type="fig"}): Fig. 1.Procedures of prioritization by *regSNPs*. In the first step (**A**), the candidate SNPs are prioritized by their effects on the binding affinity of each transcription factor. Second (**B**), a set of training genes, collected from OMIM or Ingenuity, is used to prioritize the genome-wide transcription factors with respect to the studied phenotype/disease, using Endeavour. In the third step (**C**), overall rankings, characterizing the transcription regulatory roles of candidate SNPs in phenotype/disease, are calculated based on the integration of ranks of SNPs in each transcription factor (step 1) and ranks of transcription factors to phenotype/disease (Step 2). In principle, if one SNP highly alters the binding of one transcription factor which is highly related to the phenotype/disease being studied, the SNP should be prioritized as one regulatory SNP with strong confidence. TSS: transcription start site

### 3.1.1 Test whether the SNP is within a target sequence of a known transcription factor and prioritize its effect on binding affinity {#SEC3.1.1}

If a SNP falls within a TFBS, we computed the binding affinities of both the reference and alternative alleles to the transcription factor, as measured by the matching scores (*S*~*VR*~ and *S*~*VA*~) calculated as Equation ([1](#M1){ref-type="disp-formula"}) ([Section 2](#SEC2){ref-type="sec"}), based on the sum of the logarithmic transformations of the frequencies of each nucleotide in a known binding site that was documented as a PWM in the TRANSFAC database ([@B44]). This is a standard estimation of protein--DNA binding affinity. For each TFBS, we calculated the distributions of matching scores for both binding and non-binding events ([Fig. 2](#F2){ref-type="fig"}A and [Section 2](#SEC2){ref-type="sec"}). Intuitively, if one specific SNP were predicted to cause the matching score to shift from within the non-binding distribution to within the binding distribution, or vice versa, then this SNP could contribute to the gain or loss of binding affinity, respectively. Based on this principle, we calculated the effect of a SNP on the binding affinity of a transcription factor (Δ *S*(V) calculated as Equation ([2](#M2){ref-type="disp-formula"}) in [Section 2](#SEC2){ref-type="sec"}), and subsequently compared the effect to 10000 randomly selected negative SNPs, which are not known to influence transcription factor binding, to calculate a P-value (see [Section 2](#SEC2){ref-type="sec"}) for quantifying the likelihood that the observed SNP would change the protein-DNA binding affinity of a particular transcription factor ([Fig. 2](#F2){ref-type="fig"}B). Fig. 2.The effect of one SNP on the binding affinity of a specific transcription factor. (**A**). Binding patterns of TFBS M00803 for E2F1. The red distribution represents matching scores from binding events and the blue distribution represents matching scores from non-binding events. For a candidate SNP, *S*~*VR*~ and *S*~*VA*~ characterize the binding affinities of the reference and alternative alleles to the transcription factor, respectively. Then, four intersects from these binding patterns corresponds to the candidate SNP, including *f*~*n*,*tf*~(*S*~*VR*~), *f*~*n*,*tf*~(*S*~*VA*~), *f*~*b*,*tf*~(*S*~*VR*~) and *f*~*b*,*tf*~(*S*~*VA*~). And the SNP\'s effect on the binding affinity of the transcription factor (Δ*S*~*v*~) can be calculated based on the two binding patterns and four intersects, as characterized in Equation ([2](#M2){ref-type="disp-formula"}). (**B**) Distribution of Δ*S*~*tf*~ score from 10 000 random SNPs which may or not take influence on M00761 binding. A two-tail *P*-value calculation method is used to calculate candidate SNPs\' significant *P*-value

### 3.1.2 Prioritize transcription factors that are related to a specific disease/phenotype {#SEC3.1.2}

In this step, we used *Endeavour* ([@B1]), a knowledge-learning tool for gene prioritization, to rank transcription factors by their relevance to the phenotype being investigated. *Endeavour* prioritizes candidate genes on the basis of how similar a candidate gene was to a profile derived from genes already known to be involved in the specific biological process (training set). Here, human transcription factors selected from the TRANSFAC database ([Supplementary Data](http://bioinformatics.oxfordjournals.org/cgi/content/full/bts275/DC1) 1) were treated as candidate genes. Genes known to be involved in certain biological disease/phenotype features were collected from OMIM (Online Mendelian Inheritance in Man) ([@B28]) and/or Ingenuity Pathway Analysis (IPA) software (<http://www.ingenuity.com/>), and were then used as the training set. The *Endeavour* program assigned a rank to each transcription factor based upon how likely it was to be involved in the disease/phenotype being studied.

### 3.1.3 Identify a subset of SNPs that are likely to affect the binding of transcription factors important to the phenotype/disease {#SEC3.1.3}

In this step, we defined a score for each SNP that weighted the likelihood that the observed SNP affected the binding of a transcription factor as well as the likelihood that the transcription factors were important to the phenotype/disease of interest \[*PS* calculated as Equation ([3](#M3){ref-type="disp-formula"}) in [Section 2](#SEC2){ref-type="sec"}\]. The lower the score is, the higher the likelihood that the SNP in question would affect transcriptional regulation related to the disease/phenotype. To evaluate the statistical significance of candidate SNPs, we performed permutation analysis by randomly selecting HapMap SNPs ([@B15]) within promoter regions of human protein coding genes, and by randomizing the ranking of the transcription factors with respect to phenotypes ([Section 2](#SEC2){ref-type="sec"}). This allowed calculation of the FDR for each candidate SNP.

3.2 Evaluation of *regSNPs* using promoter mutations in the HGMD {#SEC3.2}
----------------------------------------------------------------

The HGMD ([@B41]) documents known mutations causing human inherited disease, as well as disease-associated and/or functional polymorphisms reported in the literature. It does not include mutations that lack phenotypic consequences. To evaluate the performance of our strategy for prioritizing regulatory SNPs, we tested the ability of *regSNPs* to select disease-causing regulatory SNPs/mutations (positive set) from an equal number of randomly selected regulatory HapMap SNPs (negative set).

We selected for evaluation 13 different disease states ([Table 1](#T1){ref-type="table"}), based on having ≥9 disease-causing mutations from promoter regions recorded in HGMD and with at least two disease-associated genes in OMIM. For each disease state, we extracted the disease-causing promoter regulatory SNPs/mutations from HGMD and constructed a negative dataset of an equal number of randomly selected regulatory SNPs from the HapMap database. For example, in the case of diabetes, 40 SNPs/mutations in promoter regions that have been reported (in HGMD) to be associated with diabetes were the positive dataset, while 40 randomly selected regulatory SNPs from HapMap were used as the negative set. It should be appreciated that it is conceivable, albeit rather unlikely, that some of the selected SNPs in the negative set may have exert a functional effect in the development of diabetes. Then, the balanced evaluation set (positive set + negative set) for each respective disease state was assessed using *regSNPs*. A *PS* score \[Equation ([3](#M3){ref-type="disp-formula"}) in [Section 2](#SEC2){ref-type="sec"}\] was calculated for each variant, where lower values corresponded to a more significant relationship with the disease. Then, a ROC curve was constructed based upon the true positives, true negatives, false positives and false negatives, calculated at different score thresholds. For each disease state, we performed 1000 iterations with a different negative set randomly sampled from the HapMap promoter SNPs ([Section 2](#SEC2){ref-type="sec"}). The average AUC of ROCs from the 1000 iterations was plotted as shown in [Figure 3](#F3){ref-type="fig"}A. The precision of the proposed methodology varied among the 13 diseases. Breast cancer showed the highest precision (AUC = 77.9%), whereas schizophrenia had the lowest (AUC = 53.7%). Fig. 3.The AUC of the ROC for prioritization of 13 diseases and predicted associations between transcription factors and selected diseases. (**A**) ROC area (horizontal axis) of different diseases as well as the numbers (vertical axis) of tested promoter mutations in diseases. Thirteen diseases as alphabetical ranked in vertical. (**B**) Sixty-nine gene symbols of transcription factors, 13 diseases and 147 associations are included in this network, where solid small circles represent TFs and rounded rectangles represent diseases. Transcription factors associated with more than two diseases are inside the circle area of disease rectangles, those with fewer are outside Table 1.Validated diseases in OMIM and HGMDDiseaseRelated genes in OMIMRelated mutations in HGMDPromoter region mutationsDiabetes576040Thalassaemia55643Obesity243018Hemophilia22825Hypertension192516Alzheimer disease142319Schizophrenia202217Hypercholesterolemia92019Myocardial infarction141912Lung cancer221613Prostate cancer171410Colorectal cancer311410Breast cancer25129

A major advantage of *regSNPs* is that it not only selects the DNA variants that are associated with a specific phenotype, but also identifies the transcription factors whose DNA binding affinities are putatively affected by the variant in question. [Supplementary Data](http://bioinformatics.oxfordjournals.org/cgi/content/full/bts275/DC1) 2 lists the 69 different transcription factors whose DNA binding affinity was predicted to be affected by the 251 selected HGMD regulatory SNPs/mutations from the 13 different disease states under study. A bipartite graph was created to describe the network of 147 distinct relationships between the 13 disease states and the 69 transcription factors ([Fig. 3](#F3){ref-type="fig"}B), where circles and rectangles represented transcription factors and diseases, respectively. An association (represented by an edge in the network in [Fig. 3](#F3){ref-type="fig"}B) was placed between a transcription factor and a disease if the binding of that transcription factor was potentially affected by one of the mutations held to be responsible (HGMD) for the disease. Interestingly, HNF4α (hepatocyte nuclear factor 4, alpha) was predicted to be important in 9 of the 13 selected disease states, including breast cancer, diabetes, hemophilia, prostate cancer, Alzheimer disease, obesity, thalassaemia, hypertension and myocardial infarction. In addition, a total of 10 transcription factors were found to be associated with more than 3 of the 13 disease states, including E2F1 (7), p300 (7), SOX-9 (6), p53 (6), PPARα (peroxisome proliferator-activated receptor α, 5), VDR (vitamin D receptor, 5), C/EBPβ (4), FoxO3A (Forkhead box O3, 4), RXRα (Retinoic acid receptor α, 4) and YY1 (4).

3.3 Prioritizing SNPs in the genetic regions associated with BMD {#SEC3.3}
----------------------------------------------------------------

We applied *regSNPs* to prioritize regulatory SNPs within the genetic regions known to be associated with BMD from a list of candidate SNPs in the HapMap database. We previously reported that a linkage disequilibrium block on chromosome 1q is associated with BMD ([@B21]). This region was initially identified through linkage analysis using spine BMD as the phenotype of interest ([@B11]). Later, SNPs were genotyped across the linkage region and evidence of association with both spine and femoral neck BMD was identified in a 230 kb LD block ([@B21]). Due to the extensive LD within the region, we could not determine which of the 11 candidate genes within this region was contributing to the variation in BMD. According to the HapMap CEU population records, 51 SNPs were in gene promoter regions within this block. We then used *regSNPs* to ascertain which of these SNPs would be most likely to affect transcription factor binding affinities, our tacit assumption being that SNPs which affect transcription factor binding would also have a high likelihood of altering gene expression/regulation.

First, all 51 promoter SNPs within the 230 kb LD block in chromosome 1q were evaluated for their potential to affect the binding affinities of known human transcription factors. In this study, we focused on 323 human transcription factors, whose PWMs, a commonly used representation of the DNA binding motifs, were available in the TRANSFAC database version 9.2 ([@B44]). The empirical *P*-value ([Section 2](#SEC2){ref-type="sec"}) was calculated for each SNP-transcription factor pair.

Second, existing bioinformatics tools, including the IPA software (<http://www.ingenuity.com/>) and *Endeavour* ([@B1]) were used to evaluate the potential impact of individual transcription factors based upon their relevance to bone biology. We used IPA software to compile a list of genes whose functions are related to bone biology. A total of 869 genes were retrieved using IPA software by querying bone-related genes in the system ([Supplementary Data 3](http://bioinformatics.oxfordjournals.org/cgi/content/full/bts275/DC1)). We then used *Endeavour* software to rank the 323 transcription factors according to how relevant a transcription factor was to the 869 genes that are related to biology, based upon prior information including functional annotations, protein--protein interactions, expression data and other information in literature ([@B1]). *Endeavour* provided a score that evaluated the relationship between different transcription factors and bone biology. Top ranking transcription factors include p53, STAT1, p65 and E2F1 etc.; the full ranking of these transcription factors is listed in [Supplementary Data 4](http://bioinformatics.oxfordjournals.org/cgi/content/full/bts275/DC1).

Third, the *regSNPs* scores were calculated by jointly considering the capabilities of the 51 SNPs to affect transcription factor binding and the relevance of the affected transcription factors to bone biology ([Section 2](#SEC2){ref-type="sec"}). Three SNPs received lowest scores with FDR ≤25%. These three SNPs, rs34612917, rs11265251 and rs6661009, reside in the regulatory regions of the following genes: *SLC39A1* (solute carrier family 39, zinc transporter, member 1), *TPM3* (tropomyosin 3) and *CREB3L4* (cAMP responsive element binding protein 3-like 4) ([Table 2](#T2){ref-type="table"}). These SNPs are predicted to affect the binding affinities of p53 (tumor protein p53), p65 (v-rel reticuloendotheliosis viral oncogene homolog A) and E2F1 (E2F transcription factor 1), respectively. The sequence logos, a form of graphical representation of nucleic acid multiple sequence alignment ([@B38]), for the binding sites of these three transcription factors are shown in [Figure 4](#F4){ref-type="fig"}A. Clearly, all three SNP sites are located at positions that allow less degeneracy (i.e. larger letters), and therefore have the potential to dramatically alter the binding affinities of their cognate transcription factors. The allele frequencies of these three sites vary quite markedly. Thus, with rs34612917, only 0.5% of the Caucasian population contains the T allele, a variant that may cause the loss of binding of p53. The other two SNPs, rs11265251 (60.6% A, 39.4% G) and rs6661009 (58.8% A, 41.2% C) exhibit much higher minor allele frequencies, which may give rise to gain of binding of p65 and E2F1, respectively. Fig. 4.Top prioritized SNPs in BMD and luciferase reporter assay validation. (**A**) Detailed binding alterations by three top prioritized SNPs in BMD. Three transcription factors, with detailed disrupted positions in their binding sites, are shown in the form of sequence logos. The names of transcription factors, rsID of SNPs and allele frequencies of SNPs are marked. For each SNP, the left allele and right allele with an arrow separated, are the reference and alternative alleles, respectively, based on Caucasian population in HapMap. (**B**) Relative promoter strengths determined by luciferase reporter assay. RU: relative units. \**P*!\<!0.01 compared with alternative alleles that are predicted to disrupt binding of transcription factors Table 2.Top SNPs in a bone-related LD block in chromosome 1qSNP*PS(v)*GeneLocationTFBSTFFDRrs346129170.00062SLC39A1−1692M00761p530.25rs112652510.00098TPM3−1365M00054p650.25rs66610090.00110SLC39A1/CREB3L4−551/+342M00803E2F10.25[^2]

3.4 Biological validation of selected SNPs {#SEC3.4}
------------------------------------------

To verify the ability of the predicted SNPs to modulate transcription, *SLC39A1* and *TPM3* promoters harboring rs6661009 and rs11265251 were cloned upstream of a luciferase reporter gene ([Section 2](#SEC2){ref-type="sec"}). SNP rs34612917 was excluded from this validation because of its very low minor allele frequency in the general population. The luciferase activities for both alleles of rs11265251 (residing in the *TPM3* promoter) were lower than the basic pGLuc vector (background) activity. This may be due to the low activity of the *TPM3* promoter in HEK293 cells, the cell system used to test the promoter activity. Consistent with this interpretation, the expression level of the *TPM3* gene was found to be low in kidney cells and in all fetal tissues, as documented in the microarray gene expression database at the UCSC Genome Browser website ([@B14]). In contrast, luciferase assays demonstrated that SNP rs6661009 significantly altered the activity of the *SLC39A1* promoter ([Fig. 4](#F4){ref-type="fig"}B). Our original prediction by *regSNPs* was that the A allele of rs6661009 would disrupt the binding of E2F1 to the *SLC39A1* promoter; however, *in vitro* the A allele induced 58% higher luciferase activity (*P*=0.00075; [Fig. 4](#F4){ref-type="fig"}B). It has been reported that E2F1 can serve as both positive and negative regulator on their target genes ([@B7]; [@B8]; [@B40]).

4 DISCUSSION {#SEC4}
============

In this study, we proposed a three-step bioinformatics approach to identify functional SNPs within the regulatory regions following GWAS. Promoter regions were used as an example of regulatory regions to illustrate the procedures involved. First, we tested whether the identified variant is within the target sequence of a known transcription factor and hence could affect its binding affinity. Second, we prioritized those transcription factors that are related to a specific phenotype. Third, we identified a subset of sequence variants that are likely to affect the binding of a transcription factors important to the disease/phenotype under study. We tested the performance of *regSNPs* in identifying the promoter mutations in 13 diseases, using experimentally validated SNPs from HGMD. The results of this analysis showed that the prioritization was sufficiently high and could be useful, at least in some disease states (e.g. breast cancer: 77.9%). Our analysis also shows that some transcription factors (e.g. HNF4α) may play a key role in multiple disease states. Finally, our model identified three putative functional promoter SNPs, with a FDR estimated to be 25%, in a region that influences BMD. We demonstrated that one of these SNPs, rs6661009, significantly altered luciferase activity between the A and C alleles, suggesting that *regSNPs* has identified a causal SNP associated with BMD. The direction of effect, in which the variant predicted to reduce binding of a transcription factor increased promoter activity, could be due to assembly of an alternative promoter complex in the cells used. It is also reported that the E2F1 binding can be associated with both positive and negative regulation on the target genes ([@B7]; [@B8]; [@B40]).

*regSNPs* offers several major improvements over other methods used for SNP prioritization. First, it is a phenotype-specific approach to prioritize functional regulatory variants, while most existing methods ([@B5]; [@B27]; [@B33]; [@B45]) only generate putative candidates based on the sequence composition of the TFBSs, irrespective of whether the specific transcription factor is functionally important in the disease or phenotypic status. By integrating different bioinformatics tools and databases (*Endeavour* and IPA/OMIM), *regSNPs* has the advantage of narrowing the search to those transcription factors that are likely to influence the phenotype of interest. Second, unlike the previous methods, which only yield the putative SNPs, *regSNPs* identifies SNPs as well as the transcription factors which are most likely to influence the phenotype. The identified transcription factors associated with specific phenotypes provide candidate proteins for further research. Third, statistical evaluation is included in the *regSNPs* output that allows quantification of the false positive rate that can be placed in the prioritizations. Thus, at each step, a *P*-value indicates the likelihood that a given SNP will alter transcription factor-binding affinity, the likelihood of an association between a transcription factor and a specific phenotype, and the likelihood of a particular SNP exerting a regulatory role in the context of a specific phenotype. This statistical information will enable investigators to prioritize particular genes/SNPs for more in depth molecular study.

When we used *regSNPs* to analyze promoter mutations from HGMD to test the program, we found variable utility across disease states, ranging from 53.7% (schizophrenia) to 77.9% (breast cancer). One reason for this variability may be that some disease genes are more heavily reliant upon genetic regulation, and are therefore likely to be more sensitive to the influence of polymorphic variation within promoter regions. Breast cancer is a widely studied disease, reported to be highly associated with gene regulation ([@B10]). Thus, when ranking validated disease-associated promoter mutations (positives) with randomly selected SNPs (negatives), reasonably high precision can be achieved. In contrast, in the case of complex traits, such as hypertension, their pathophysiological mechanisms involve multiple genetic factors together with a potent environmental influence ([@B26]; [@B34]; [@B37]; [@B39]); in such cases, the ability of regulatory variant identification may be limited.

Limitations of *regSNPs* include its reliance on existing knowledge (e.g. disease/phenotype-related genes, and binding models for transcription factors). Despite these, *regSNPs* provides an important strategy for prioritizing causal regulatory DNA variants with respect to specific disease/phenotype of interest. It is especially valuable for prioritizing candidate SNPs identified by the GWAS, or novel or rare variants discovered from the direct human genome sequencing.
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